PL2667715T3 - Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego - Google Patents

Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego

Info

Publication number
PL2667715T3
PL2667715T3 PL12739509T PL12739509T PL2667715T3 PL 2667715 T3 PL2667715 T3 PL 2667715T3 PL 12739509 T PL12739509 T PL 12739509T PL 12739509 T PL12739509 T PL 12739509T PL 2667715 T3 PL2667715 T3 PL 2667715T3
Authority
PL
Poland
Prior art keywords
methylprolyl
glycyl
treatment
glutamic acid
autism spectrum
Prior art date
Application number
PL12739509T
Other languages
English (en)
Inventor
Larry Glass
Michael John Bickerdike
Michael Frederick Snape
Original Assignee
Neuren Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Limited filed Critical Neuren Pharmaceuticals Limited
Publication of PL2667715T3 publication Critical patent/PL2667715T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12739509T 2011-01-27 2012-01-27 Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego PL2667715T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161462141P 2011-01-27 2011-01-27
US201161492248P 2011-06-01 2011-06-01
PCT/US2012/000047 WO2012102832A1 (en) 2011-01-27 2012-01-27 Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid
EP12739509.3A EP2667715B1 (en) 2011-01-27 2012-01-27 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Publications (1)

Publication Number Publication Date
PL2667715T3 true PL2667715T3 (pl) 2018-02-28

Family

ID=46581110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12739509T PL2667715T3 (pl) 2011-01-27 2012-01-27 Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego

Country Status (20)

Country Link
US (2) US9708366B2 (pl)
EP (1) EP2667715B1 (pl)
JP (3) JP6348283B2 (pl)
AU (1) AU2012209466C1 (pl)
BR (1) BR112013018898B1 (pl)
CA (1) CA2823218C (pl)
CO (1) CO6791613A2 (pl)
CY (1) CY1119455T1 (pl)
DK (1) DK2667715T3 (pl)
ES (1) ES2641880T3 (pl)
HR (1) HRP20171478T1 (pl)
HU (1) HUE036637T2 (pl)
IL (1) IL227669B (pl)
LT (1) LT2667715T (pl)
PL (1) PL2667715T3 (pl)
PT (1) PT2667715T (pl)
RS (1) RS56461B1 (pl)
SI (1) SI2667715T1 (pl)
SM (1) SMT201700485T1 (pl)
WO (1) WO2012102832A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700485T1 (it) 2011-01-27 2017-11-15 Neuren Pharmaceuticals Ltd Trattamento di disturbi dello spettro autistico usando acido glicil-l-2-metilprolil-l-glutammico
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−l−2−メチルプロリル−l−グルタミン酸を使用する自閉症スペクトラム障害の処置
SI3024463T1 (sl) * 2013-07-25 2020-08-31 Neuren Pharmaceuticals Limited Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj
SG11201602161XA (en) 2013-09-23 2016-04-28 Wolff August Gmbh & Co Kg Arzneimittel Dr Anti-inflammatory tripeptides
ES3014042T3 (en) * 2014-06-06 2025-04-16 Meizon Innovation 2 Pty Ltd Trans-10-hydroxy-2-decenoic acid for use in the treatment of autism spectrum disorder
RU2608444C1 (ru) * 2015-10-02 2017-01-18 Закрытое Акционерное Общество "Алмаз Фарм" Средство для лечения и профилактики расстройств аутистического спектра
US20180296647A1 (en) 2015-10-14 2018-10-18 Kurume University Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
JP2019514961A (ja) * 2016-05-04 2019-06-06 ニューロトロープ バイオサイエンス インコーポレイテッド レット症候群を処置するための方法及び組成物
JP7182554B2 (ja) 2016-11-14 2022-12-02 コグノア,インク. 発達に係る疾病を評価し、およびカバー率と信頼度に対する制御を提供する方法および装置
PL3570940T3 (pl) * 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EP3580700A4 (en) 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
CA3128037A1 (en) * 2019-02-01 2020-08-06 Revivo Therapeutics Nomethiazoles as a treatment for rett syndrome
KR102643554B1 (ko) * 2019-03-22 2024-03-04 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
KR20220059479A (ko) * 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
WO2021086892A1 (en) * 2019-10-28 2021-05-06 Acadia Pharmaceuticals Inc. Methods and compositions for treatment of rett syndrome
EP4138880A4 (en) * 2020-04-24 2024-08-07 New York University Use of igf-2 for treatment of epileptic seizures
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.
IL310045A (en) * 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of trofinetide
CN114128672B (zh) * 2021-11-21 2023-04-07 河南省儿童医院郑州儿童医院 一种孤独症大鼠模型的构建方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DK15888D0 (da) 1988-01-14 1988-01-14 Carlsberg Biotechnology Ltd Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
WO1998014202A1 (en) 1996-10-04 1998-04-09 Auckland Uniservices Limited Regulation of neural enzymes
EP1087782A4 (en) 1998-06-15 2001-09-12 Neuronz Ltd REGULATION OF TYROSINE HYDROXYLASE
BR0015025A (pt) * 1999-10-26 2002-06-18 Janssen Pharmaceutica Nv Solução oral contendo galantamina e um agente adoçante
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US20070004641A1 (en) 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
ES2325983T3 (es) 2001-05-24 2009-09-28 Neuren Pharmaceuticals Limited Analogos y peptidomimeticos de gpe.
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714070B2 (en) 2002-08-27 2010-05-11 Sunoco Chemicals, Inc. In-reactor produced polypropylene blends
AU2005286943A1 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
JP5220724B2 (ja) * 2006-03-14 2013-06-26 ニューレン ファーマシューティカルズ リミテッド グリシル−2−メチルプロリルグルタミン酸塩の経口製剤
GB0707127D0 (en) * 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
CA2689549A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
AU2010204995A1 (en) 2009-01-16 2011-08-18 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
WO2011146109A2 (en) 2010-05-17 2011-11-24 Mount Sinai School Of Medicine Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
SMT201700485T1 (it) 2011-01-27 2017-11-15 Neuren Pharmaceuticals Ltd Trattamento di disturbi dello spettro autistico usando acido glicil-l-2-metilprolil-l-glutammico

Also Published As

Publication number Publication date
EP2667715B1 (en) 2017-07-19
SMT201700485T1 (it) 2017-11-15
JP2014508744A (ja) 2014-04-10
HUE036637T2 (hu) 2018-07-30
HRP20171478T1 (hr) 2017-11-17
JP6640275B2 (ja) 2020-02-05
RS56461B1 (sr) 2018-01-31
WO2012102832A1 (en) 2012-08-02
DK2667715T3 (en) 2017-10-23
CY1119455T1 (el) 2018-04-04
CA2823218A1 (en) 2012-08-02
CA2823218C (en) 2021-04-20
IL227669A0 (en) 2013-09-30
BR112013018898B1 (pt) 2021-10-05
US9212204B2 (en) 2015-12-15
CO6791613A2 (es) 2013-11-14
EP2667715A1 (en) 2013-12-04
US20150197543A1 (en) 2015-07-16
ES2641880T3 (es) 2017-11-14
LT2667715T (lt) 2017-11-10
AU2012209466B2 (en) 2016-02-25
JP2018138606A (ja) 2018-09-06
SI2667715T1 (sl) 2017-11-30
EP2667715A4 (en) 2014-07-23
IL227669B (en) 2020-06-30
AU2012209466C1 (en) 2016-06-23
US9708366B2 (en) 2017-07-18
JP6348283B2 (ja) 2018-06-27
US20140147491A1 (en) 2014-05-29
BR112013018898A2 (pt) 2017-04-18
AU2012209466A1 (en) 2013-09-05
JP6342459B2 (ja) 2018-06-13
JP2016210808A (ja) 2016-12-15
PT2667715T (pt) 2017-10-19

Similar Documents

Publication Publication Date Title
LT2667715T (lt) Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
IL226401A0 (en) Methods for treating disorders related to @fgfBA
EP2717855A4 (en) PROCESSING METHODS
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
ZA201205829B (en) Treatment of respiratory disorders
IL233111A0 (en) Preparations for the treatment of inflammation
GB201202773D0 (en) Compositions for treatment of skin disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2709665A4 (en) TREATMENT OF PSORIASIS
PL395112A1 (pl) Zastosowanie klenbuterolu do leczenia autyzmu
IL239273A0 (en) A method of treating diseases
ZA201308194B (en) Treatment of mastitis
GB201107467D0 (en) Novel treatment of pain
EP2791324A4 (en) PROCESSING METHOD
GB201218263D0 (en) Treatment of autism
GB201101773D0 (en) Treatment of inflammatory disorders
GB201101183D0 (en) Treatment of neurodegenerative disorders
GB201100651D0 (en) Treatment of inflammation
GB201119458D0 (en) Compositions for treatment of sleep disorders
GB201118065D0 (en) Treatment of movement disorders
GB201110602D0 (en) Methods of treatment
GB201109737D0 (en) Methods of treatment
GB201121044D0 (en) Treatment of solutions
IL228973A0 (en) Oxymetazoline for the treatment of anorectal disorders